PRINCETON, N.J., Feb. 17, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Jeffrey Freitag, M.D., Senior Vice President, PharmaNet Consulting, will expand his role to become Chief Medical Officer (CMO) of PharmaNet. In this position, he will be the senior medical representative for the Company and provide guidance to the Company's many physicians who are involved in designing and monitoring Phase I through Phase III clinical trials. He will also retain his current responsibilities heading PharmaNet's team of regulatory and pharmaceutical consultants which provide strategic drug development advice to clients."Excellence in pharmaceutical science and medicine is critical to the success of PharmaNet and its clients. We are therefore very pleased that Dr. Jeffrey Freitag, an accomplished internist and nephrologist, will be serving in the role of CMO," said Dr. Tom Newman, President of PharmaNet Development Group.
Dr. Freitag has worked in the pharmaceutical industry for over twenty-five years in a variety of positions including Vice President, Clinical Drug Development at The Liposome Company, Senior Vice President of Medical Affairs at PharmaNet and most recently as Vice President of Research & Development at Bone Care International before rejoining PharmaNet in 2006. Dr. Freitag is board certified in both Internal Medicine and Nephrology and has a strong academic, scientific and clinical background. He has extensive experience in providing medical and scientific direction and leadership to product development teams. He has also provided strategic clinical development consultation to clients in a variety of therapeutic areas including renal, pulmonary, cardiovascular, oncology and infectious disease therapeutic areas.
About PharmaNet Development Group, Inc.PharmaNet Development Grou